NetworkNewsBreaks – Semnur Pharmaceuticals, Inc.’s (NASDAQ: SRNE) SP-102 Phase 1/2 Trial Meets Primary Endpoint, Preparing for Safety and Efficacy Studies; Shares Surge

Shares of Semnur Pharmaceuticals (NASDAQ: SRNE) are up 12.1% after the company posted positive data from is phase 1/2 pharmacokinetic bridging trial of its lead product, SP-102, for the treatment of lumbar radicular pain. The trial achieved its primary pharmacokinetic endpoint and demonstrated that a single epidural injection of SP-102 can provide a sustained analgesic effect for one month. Semnur said it will now move forward with the next stage of clinical trials. “We are very excited with the data from this first-in-human proof-of-principle study, which allows us to proceed with the planned Phase 3 safety and efficacy trials in the U.S. SP-102 is designed to address the limitations of existing steroid formulations, which are used off-label for the treatment of lumbar radicular pain, and has a strong potential to meet the current unmet medical needs. We anticipate sharing more details from the Phase 1/2 trial at upcoming meetings and with the expectation to start the pivotal multi-center U.S. Phase 3 trial this year,” Semnur Chief Medical Officer Dmitri Lissin, MD, stated in the news release. Semnur trades in a 52-week range of $1.50-$8.35.

To view the full press release, visit: http://nnw.fm/vvqR2

About Semnur Pharmaceuticals Inc.

Semnur Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company based in Los Altos, CA, focused on the development and commercialization of best in class novel non-opioid pain therapies. Semnur’s lead program, SP-102, is a non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica. For more information, visit www.semnurpharma.com.

About NetworkNewsBreaks

NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s